Lowest Price Guaranteed
Pages
307
Last Updated
August 2026
View Count
29563
1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion
5. EXECUTIVE SUMMARY
5.1. Executive Summary: Market Landscape
5.2. Executive Summary: Market Trends
5.3. Executive Summary: Market Forecast and Opportunity Analysis
6. INTRODUCTION
6.1. Chapter Overview
6.2. History of Cancer
6.3. Biological Characteristics Exhibited by Cancer Cells
6.4. Treatment Modalities for Cancer
6.5. Targeted Therapies
6.6. Cancer Targets: Focus on Transcription Factors, GTPases, Phosphatases and G-Protein Coupled Receptors (GPCRs)
6.7. Types of Undruggable Cancer Targets
6.7.1. Transcription Factors
6.7.2. GTPases
6.7.3. Phosphatases
6.7.4. GPCRs
6.8. Conclusion
7. MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Overall Market
7.3. Clinical Pipeline
7.3.1. Analysis by Target Indication
7.3.2. Analysis by Type of Molecule
7.3.3. Analysis by Route of Administration
7.3.4. Analysis by Target Family
7.4. Preclinical Pipeline
7.4.1. Analysis by Target Indication
7.4.2. Analysis by Type of Molecule
7.4.3. Analysis by Target Family
8. COMPANY PROFILES
8.1. Chapter Overview
8.2. AbbVie*
8.2.1. Company Overview
8.2.2. Product Portfolio
8.2.3. Recent Developments and Future Outlook
* Similar details are presented for other companies mentioned below (based on information in the public domain)
8.3. AstraZeneca
8.4. Bristol Myers Squibb
8.5. Circio
8.6. Daiichi Sankyo
8.7. Gilead Sciences
8.8. Johnson & Johnson
8.9. Merck
8.10. Novartis
8.11. Pfizer
8.12. Roche
9. TECHNOLOGY LANDSCAPE
9.1. Chapter Overview
9.2. Overall Landscape of Technologies
9.3. Drug Discovery Platforms
9.3.1. 3-Dimensional Bubble Analysis
9.4. Drug Development Platforms
10. PUBLICATION AND GRANT ANALYSIS
10.1. Chapter Overview
10.2. List of Publications
10.2.1. Analysis by Year of Publication
10.2.2. Analysis by Key Journals
10.2.3. Analysis by Popular Targets
10.2.4. Analysis by Popular Drug Classes
10.2.5. Analysis by Target Indications
10.3. List of Grants
10.3.1. Analysis by Types of Grants
10.3.2. Analysis by Key Research Areas
10.3.3. Analysis by Most Active Players
11. VENTURE FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. Funding and Investment Analysis
11.3.1. Analysis by Year of Funding Instances
11.3.2. Analysis by Amount Invested
11.3.3. Analysis by Type of Funding
11.3.4. Analysis by Number of Instances and Amount Invested: Most Active Players
11.3.5. Analysis by Number of Funding Instances: Most Active Investors
11.3.6. Analysis by Geography
12. PARTNERSHIP AND COLLABORATION ANALYSIS
12.1. Chapter Overview
12.2. Types of Partnership Models
12.3. List of Partnerships
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership Model
12.3.3. Analysis by Key Focus Area
12.3.4. Analysis by Number of Partnerships: Most Active Players
13. GLOBAL CANCER THERAPEUTICS MARKET
13.1. Chapter Overview
13.2. Assumptions and Methodology
13.3. Global Cancer Therapeutics Market, Forecasted Estimates (till 2035)
13.4. Roots Analysis Perspective on Market Growth
13.5. Scenario Analysis
13.5.1. Conservative Scenario
13.5.2. Optimistic Scenario
13.6. Key Market Segmentations
14. CANCER THERAPEUTICS MARKET, BY TYPE OF THERAPY
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Cancer Therapeutics Market: Distribution by Type of Therapy
14.3.1. Cancer Therapeutics Market for Chemotherapies, Forecasted Estimates (till 2035)
14.3.2. Cancer Therapeutics Market for Hormonal Therapies, Forecasted Estimates (till 2035)
14.3.3. Cancer Therapeutics Market for Immunotherapies, Forecasted Estimates (till 2035)
14.3.4. Cancer Therapeutics Market for Targeted Therapies, Forecasted Estimates (till 2035)
14.3.5. Cancer Therapeutics Market for Other Therapies, Forecasted Estimates (till 2035)
14.4. Data Triangulation and Validation
15. CANCER THERAPEUTICS MARKET, BY APPLICATION
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Cancer Therapeutics Market: Distribution by Application
15.3.1. Cancer Therapeutics Market for Blood Cancer, Forecasted Estimates (till 2035)
15.3.2. Cancer Therapeutics Market for Breast Cancer, Forecasted Estimates (till 2035)
15.3.3. Cancer Therapeutics Market for Cervical Cancer, Forecasted Estimates (till 2035)
15.3.4. Cancer Therapeutics Market for Colorectal Cancer, Forecasted Estimates (till 2035)
15.3.5. Cancer Therapeutics Market for Glioblastoma, Forecasted Estimates (till 2035)
15.3.6. Cancer Therapeutics Market for Head and Neck Cancer, Forecasted Estimates (till 2035)
15.3.7. Cancer Therapeutics Market for Lung Cancer, Forecasted Estimates (till 2035)
15.3.8. Cancer Therapeutics Market for Malignant Meningioma, Forecasted Estimates (till 2035)
15.3.9. Cancer Therapeutics Market for Melanoma, Forecasted Estimates (till 2035)
15.3.10. Cancer Therapeutics Market for Mesothelioma, Forecasted Estimates (till 2035)
15.3.11. Cancer Therapeutics Market for Prostate Cancer, Forecasted Estimates (till 2035)
15.3.12. Cancer Therapeutics Market for Others, Forecasted Estimates (till 2035)
15.4. Data Triangulation and Validation
16. CANCER THERAPEUTICS MARKET, BY KEY DRUGS
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Cancer Therapeutics Market: Distribution by Key Drugs
16.3.1. Cancer Therapeutics Market for Keytruda®, Forecasted Estimates (till 2035)
16.3.2. Cancer Therapeutics Market for Darzalex®, Forecasted Estimates (till 2035)
16.3.3. Cancer Therapeutics Market for Revlimid®, Forecasted Estimates (till 2035)
16.3.4. Cancer Therapeutics Market for Avastin®, Forecasted Estimates (till 2035)
16.3.5. Cancer Therapeutics Market for Herceptin®, Forecasted Estimates (till 2035)
16.3.6. Cancer Therapeutics Market for Rituxan®, Forecasted Estimates (till 2035)
16.3.7. Cancer Therapeutics Market for Opdivo®, Forecasted Estimates (till 2035)
16.3.8. Cancer Therapeutics Market for Gleevec®, Forecasted Estimates (till 2035)
16.3.9. Cancer Therapeutics Market for Velcade®, Forecasted Estimates (till 2035)
16.3.10. Cancer Therapeutics Market for Imbruvica®, Forecasted Estimates (till 2035)
16.3.11. Cancer Therapeutics Market for Ibrance®, Forecasted Estimates (till 2035)
16.3.12. Cancer Therapeutics Market for Zytiga®, Forecasted Estimates (till 2035)
16.3.13. Cancer Therapeutics Market for Alimta®, Forecasted Estimates (till 2035)
16.3.14. Cancer Therapeutics Market for Xtandi®, Forecasted Estimates (till 2035)
16.3.15. Cancer Therapeutics Market for Tarceva®, Forecasted Estimates (till 2035)
16.3.16. Cancer Therapeutics Market for Perjeta®, Forecasted Estimates (till 2035)
16.3.17. Cancer Therapeutics Market for Temodar®, Forecasted Estimates (till 2035)
16.3.18. Cancer Therapeutics Market for Others, Forecasted Estimates (till 2035)
16.4. Data Triangulation and Validation
17. CANCER THERAPEUTICS MARKET, BY END USER
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Cancer Therapeutics Market: Distribution by End User
17.3.1. Cancer Therapeutics Market for Cancer and Radiation Therapy Centers, Forecasted Estimates (till 2035)
17.3.2. Cancer Therapeutics Market for Hospitals, Forecasted Estimates (till 2035)
17.3.3. Cancer Therapeutics Market for Specialty Clinics, Forecasted Estimates (till 2035)
17.4. Data Triangulation and Validation
18. CANCER THERAPEUTICS MARKET, BY GEOGRAPHICAL REGIONS
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Cancer Therapeutics Market: Distribution by Geographical Regions
18.3.1. Cancer Therapeutics Market in North America, Forecasted Estimates (till 2035)
18.3.2. Cancer Therapeutics Market in Europe, Forecasted Estimates (till 2035)
18.3.3. Cancer Therapeutics Market in Asia-Pacific, Forecasted Estimates (till 2035)
18.3.4. Cancer Therapeutics Market in Middle East and North Africa, Forecasted Estimates (till 2035)
18.3.5. Cancer Therapeutics Market in Latin America, Forecasted Estimates (till 2035)
18.4. Market Dynamics Assessment
18.4.1. Penetration-Growth (P-G) Matrix
18.5. Data Triangulation and Validation
19. CONCLUDING REMARKS
20. EXECUTIVE INSIGHTS
20.1. Company A
20.1.1. Company Overview
20.1.2. Interview Transcript: Chief Technical Officer and Former Director of Preclinical Development & Strategic Partnerships
20.2. Company B
20.2.1. Company Overview
20.2.2. Interview Transcript: Business Manager
20.3. Company C
20.3.1. Company Overview
20.3.2. Interview Transcript: Former Chief Scientific Officer
20.4. Company D
20.4.1. Company Overview
20.4.2. Interview Transcript: Associate Director of Drug Development
20.5. Company E
20.5.1. Company Overview
20.5.2. Interview Transcript: Doctor of Medicine
20.6. Company F
20.6.1. Company Overview
20.6.2. Interview Transcript: Professor
20.7. Company G
20.7.1. Company Overview
20.7.2. Interview Transcript: Doctor of Medicine
20.8. Company H
20.8.1. Company Overview
20.8.2. Interview Transcript: Professor
20.9. Company I
20.9.1. Company Overview
20.9.2. Interview Transcript: Doctor of Medicine
20.10. Company J
20.10.1. Company Overview
20.10.2. Interview Transcript: Professor
20.11. Company K
20.11.1. Company Overview
20.11.2. Interview Transcript: Oncologist
20.12. Company L
20.12.1. Company Overview
20.12.2. Interview Transcript: Professor
20.13. Company M
20.13.1. Company Overview
20.13.2. Interview Transcript: Lead of Cancer Genomics
21. APPENDIX I: TABULATED DATA
22. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Market Trends
Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Biological Characteristics Exhibited by Cancer Cells
Figure 6.2 Global Cancer Incidence
Figure 6.3 Types of Cancer Treatment
Figure 6.4 Difficult-to-Modulate Cancer Targets: Transcription Factors
Figure 6.5 Cell Proliferation Pathway of Normal and Mutant RAS Protein
Figure 6.6 Difficult-to-Modulate Cancer Targets: Phosphatases
Figure 7.1 Overall Pipeline: Distribution by Phase of Development
Figure 7.2 Overall Pipeline: Distribution by Target Indication
Figure 7.3 Overall Pipeline: Distribution by Biological Target
Figure 7.4 Clinical Pipeline: Distribution by Target Indication
Figure 7.5 Clinical Pipeline: Distribution by Type of Molecule
Figure 7.6 Clinical Pipeline: Distribution by Route of Administration
Figure 7.7 Clinical Pipeline: Distribution by Target Family
Figure 7.8 Preclinical / Discovery Pipeline: Distribution by Target Indication
Figure 7.9 Preclinical / Discovery Pipeline: Distribution by Type of Molecule
Figure 7.10 Preclinical / Discovery Pipeline: Distribution by Target Family
Figure 9.1 Technology Platforms: Geographical Distribution of Developers
Figure 9.2 Technology Platforms: Distribution by Type of Technology
Figure 9.3 Drug Discovery Platforms: 3-Dimensional Bubble Analysis
Figure 10.1 Publications: Year-wise Distribution
Figure 10.2 Publications: Popular Journals
Figure 10.3 Publications: Popular Targets
Figure 10.4 Publications: Popular Drug Classes
Figure 10.5 Publications: Target Indication
Figure 10.6 Grants: Types of Grants
Figure 10.7 Grants: Key Research Areas
Figure 10.8 Grants: Most Active Players
Figure 11.1 Funding Instances: Distribution by Year, Since 2014
Figure 11.2 Funding Instances: Distribution by Amount Invested by Year, Since 2014 (USD Billion)
Figure 11.3 Funding Instances: Distribution by Type of Funding
Figure 11.4 Funding Instances: Distribution by Amount Invested and Type of Funding (USD Billion)
Figure 11.5 Funding Instances: Most Active Players
Figure 11.6 Funding Instances: Most Active Investors
Figure 11.7 Funding Instances: Summary
Figure 11.8 Funding Instances: Distribution by Geography and Amount Invested (USD Billion)
Figure 11.9 Funding Instances: Distribution by geography and Number of Instances
Figure 12.1 Partnerships: Distribution by Year, Since 2014
Figure 12.2 Partnerships: Distribution by Type of Collaboration
Figure 12.3 Partnerships: Distribution by Key Focus Area
Figure 12.4 Partnerships: Most Active Players
Figure 13.1 Global Cancer Therapeutics Market, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 13.2 Global Cancer Therapeutics Market, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035): Conservative Scenario (USD Billion)
Figure 13.3 Global Cancer Therapeutics Market, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035): Optimistic Scenario (USD Billion)
Figure 14.1 Cancer Therapeutics Market: Distribution by Type of Therapy (USD Billion)
Figure 14.2 Cancer Therapeutics Market for Chemotherapy, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 14.3 Cancer Therapeutics Market for Hormonal Therapies, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 14.4 Cancer Therapeutics Market for Immunotherapies, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 14.5 Cancer Therapeutics Market for Targeted Therapies, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 14.6 Cancer Therapeutics Market for Other Therapies, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 15.1 Cancer Therapeutics Market: Distribution by Application (USD Billion)
Figure 15.2 Cancer Therapeutics Market for Blood Cancer, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 15.3 Cancer Therapeutics Market for Breast Cancer, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 15.4 Cancer Therapeutics Market for Cervical Cancer, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 15.5 Cancer Therapeutics Market for Colorectal Cancer, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 15.6 Cancer Therapeutics Market for Glioblastoma, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 15.7 Cancer Therapeutics Market for Head and Neck Cancer, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 15.8 Cancer Therapeutics Market for Lung Cancer, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 15.9 Cancer Therapeutics Market for Malignant Meningioma, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 15.10 Cancer Therapeutics Market for Melanoma, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 15.11 Cancer Therapeutics Market for Mesothelioma, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 15.12 Cancer Therapeutics Market for Prostate Cancer, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 15.13 Cancer Therapeutics Market for Others, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.1 Cancer Therapeutics Market: Distribution by Key Drugs (USD Billion)
Figure 16.2 Cancer Therapeutics Market for Keytruda®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.3 Cancer Therapeutics Market for Darzalex®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.4 Cancer Therapeutics Market for Revlimid®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.5 Cancer Therapeutics Market for Avastin®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.6 Cancer Therapeutics Market for Herceptin®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.7 Cancer Therapeutics Market for Rituxan®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.8 Cancer Therapeutics Market for Opdivo®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.9 Cancer Therapeutics Market for Gleevec®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.10 Cancer Therapeutics Market for Velcade®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.11 Cancer Therapeutics Market for Imbruvica®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.12 Cancer Therapeutics Market for Ibrance®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.13 Cancer Therapeutics Market for Zytiga®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.14 Cancer Therapeutics Market for Alimta®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.15 Cancer Therapeutics Market for Xtandi®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.16 Cancer Therapeutics Market for Tarceva®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.17 Cancer Therapeutics Market for Perjeta®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.18 Cancer Therapeutics Market for Temodar®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.19 Cancer Therapeutics Market for Others, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 17.1 Cancer Therapeutics Market: Distribution by End User (USD Billion)
Figure 17.2 Cancer Therapeutics Market for Cancer and Radiation Therapy Centers, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 17.3 Cancer Therapeutics Market for Hospitals, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 17.4 Cancer Therapeutics Market for Specialty Clinics, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 18.1 Cancer Therapeutics Market: Distribution by Geographical Regions (USD Billion)
Figure 18.2 Cancer Therapeutics Market in North America, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 18.3 Cancer Therapeutics Market in Europe, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 18.4 Cancer Therapeutics Market in Asia-Pacific, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 18.5 Cancer Therapeutics Market in Middle East and North Africa, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 18.6 Cancer Therapeutics Market in Latin America, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 19.1 Concluding Remarks: Market Landscape
Figure 19.2 Concluding Remarks: Publication and Grant Analysis
Figure 19.3 Concluding Remarks: Venture Funding and Investment Analysis
Figure 19.4 Concluding Remarks: Partnerships and Collaboration Analysis
Figure 19.5 Concluding Remarks: Market Sizing and Opportunity Analysis
Table 6.1 Global Incidence of Cancer
Table 6.2 Ras Mutations in Different Cancer Types (%)
Table 7.1 Clinical Pipeline
Table 7.2 Preclinical / Discovery Pipeline
Table 9.1 Drug Discovery Platforms
Table 9.2 Drug Discovery Platforms: 3-Dimensional Bubble Analysis
Table 9.3 Drug Delivery and Drug Development Platforms
Table 10.1 List of Target Specific Publications
Table 10.2 List of Other Publications
Table 10.3 List of Grants
Table 11.1 Funding and Investments, Since 2014
Table 11.2 Summary of Investments
Table 12.1 Recent Collaborations, Since 2014
Table 21.1 Overall Pipeline: Distribution by Phase of Development
Table 21.2 Overall Pipeline: Distribution by Target Indication
Table 21.3 Overall Pipeline: Distribution by Biological Target
Table 21.4 Clinical Pipeline: Distribution by Target Indication
Table 21.5 Clinical Pipeline: Distribution by Type of Molecule
Table 21.6 Clinical Pipeline: Distribution by Route of Administration
Table 21.7 Clinical Pipeline: Distribution by Target Family
Table 21.8 Preclinical / Discovery Pipeline: Distribution by Target Indication
Table 21.9 Preclinical / Discovery Pipeline: Distribution by Type of Molecule
Table 21.10 Preclinical / Discovery Pipeline: Distribution by Target Family
Table 21.11 Technology Platforms: Geographical Distribution of Developers
Table 21.12 Technology Platforms: Distribution by Type of Technology
Table 21.13 Drug Discovery Platforms: 3-Dimensional Bubble Analysis
Table 21.14 Publications: Year-wise Distribution
Table 21.15 Publications: Popular Journals
Table 21.16 Publications: Popular Targets
Table 21.17 Publications: Popular Drug Classes
Table 21.18 Publications: Target Indication
Table 21.19 Grants: Types of Grants
Table 21.20 Grants: Key Research Areas
Table 21.21 Grants: Most Active Players
Table 21.22 Funding Instances: Distribution by Year, Since 2014
Table 21.23 Funding Instances: Distribution by Amount Invested by Year, Since 2014 (USD Billion)
Table 21.24 Funding Instances: Distribution by Type of Funding
Table 21.25 Funding Instances: Distribution by Amount Invested and Type of Funding (USD Billion)
Table 21.26 Funding Instances: Most Active Players
Table 21.27 Funding Instances: Most Active Investors
Table 21.28 Funding Instances: Summary
Table 21.29 Funding Instances: Distribution by Geography and Amount Invested (USD Billion)
Table 21.30 Funding Instances: Distribution by geography and Number of Instances
Table 21.31 Partnerships: Distribution by Year, Since 2014
Table 21.32 Partnerships: Distribution by Type of Collaboration
Table 21.33 Partnerships: Distribution by Key Focus Area
Table 21.34 Partnerships: Most Active Players
Table 21.35 Global Cancer Therapeutics Market, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.36 Global Cancer Therapeutics Market, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035): Conservative Scenario (USD Billion)
Table 21.37 Global Cancer Therapeutics Market, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035): Optimistic Scenario (USD Billion)
Table 21.38 Cancer Therapeutics Market: Distribution by Type of Therapy (USD Billion)
Table 21.39 Cancer Therapeutics Market for Chemotherapies, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.40 Cancer Therapeutics Market for Hormonal Therapies, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.41 Cancer Therapeutics Market for Immunotherapies, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.42 Cancer Therapeutics Market for Targeted Therapies, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.43 Cancer Therapeutics Market for Other Therapies, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.44 Cancer Therapeutics Market: Distribution by Application (USD Billion)
Table 21.45 Cancer Therapeutics Market for Blood Cancer, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.46 Cancer Therapeutics Market for Breast Cancer, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.47 Cancer Therapeutics Market for Cervical Cancer, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.48 Cancer Therapeutics Market for Colorectal Cancer, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.49 Cancer Therapeutics Market for Glioblastoma, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.50 Cancer Therapeutics Market for Head and Neck Cancer, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.51 Cancer Therapeutics Market for Lung Cancer, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.52 Cancer Therapeutics Market for Malignant Meningioma, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.53 Cancer Therapeutics Market for Melanoma, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.54 Cancer Therapeutics Market for Mesothelioma, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.55 Cancer Therapeutics Market for Prostate Cancer, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.56 Cancer Therapeutics Market for Others, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.57 Cancer Therapeutics Market: Distribution by Key Drugs (USD Billion)
Table 21.58 Cancer Therapeutics Market for Keytruda®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.59 Cancer Therapeutics Market for Darzalex®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.60 Cancer Therapeutics Market for Revlimid®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.61 Cancer Therapeutics Market for Avastin®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.62 Cancer Therapeutics Market for Herceptin®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.63 Cancer Therapeutics Market for Rituxan®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.64 Cancer Therapeutics Market for Opdivo®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.65 Cancer Therapeutics Market for Gleevec®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.66 Cancer Therapeutics Market for Velcade®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.67 Cancer Therapeutics Market for Imbruvica®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.68 Cancer Therapeutics Market for Ibrance®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.69 Cancer Therapeutics Market for Zytiga®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.70 Cancer Therapeutics Market for Alimta®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.71 Cancer Therapeutics Market for Xtandi®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.72 Cancer Therapeutics Market for Tarceva®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.73 Cancer Therapeutics Market for Perjeta®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.74 Cancer Therapeutics Market for Temodar®, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.75 Cancer Therapeutics Market for Others, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.76 Cancer Therapeutics Market: Distribution by End User (USD Billion)
Table 21.77 Cancer Therapeutics Market for Cancer and Radiation Therapy Centers, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.78 Cancer Therapeutics Market for Hospitals, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.79 Cancer Therapeutics Market for Specialty Clinics, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.80 Cancer Therapeutics Market: Distribution by Geographical Regions (USD Billion)
Table 21.81 Cancer Therapeutics Market in North America, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.82 Cancer Therapeutics Market in Europe, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.83 Cancer Therapeutics Market in Asia-Pacific, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.84 Cancer Therapeutics Market in Middle East and North Africa, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)
Table 21.85 Cancer Therapeutics Market in Latin America, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035) (USD Billion)